Barclays Wealth and Investment Management related stories
All articles and analysis
Marathon Capital recruits Shaw as senior managing directorMarathon Capital has hired Chris Shaw as a senior managing director and head of European investment banking.
Castle Harlan promotes Yang to senior associateCastle Harlan has promoted Marilyn Yang to senior associate.
Proterra to go public through deal with ArcLight SPACProterra Inc, a provider of commercial vehicle electrification technology, will go public via a deal with ArcLight Clean Transition Corp, a blank check company.
Sagard unveils Canadian PE strategy led by ex-Clearspring partnerSagard Holdings, a subsidiary of Canadian holding company Power Corp, has launched a private equity strategy focused on the Canadian mid-market.
BPEA-backed Telus International files to go publicTelus International, an affiliate of Canadian communications and information technology company Telus Corp, has filed for a proposed initial public offering of subordinate voting shares on the New York Stock Exchange and the Toronto Stock Exchange.
CVC to sell Kount to Equifax for $640mCVC Growth Fund is set to generate a 4.7x gross return on its investment, alongside a gross IRR of 34 percent, sources told PE Hub.
AIP to buy Domtar's personal care business for $920mAmerican industrial Partners has agreed to acquire Domtar's personal care business for $920 million.
Rising Stars 2021For the second year in a row, we reached out to readers and others in the venture capital community to find out who are the industry’s up and comers. It was a difficult task, but we crafted a list of 40 professionals under 40 who are certain to shape VC as the next generation of rising stars.
VC-backed Ouster and Colonnade to mergeOuster, a provider of high-resolution digital lidar sensors, and Colonnade Acquisition Corp., a blank check company, have agreed to merge.
Nordic and Astorg to buy New Mountain Capital's Cytel in $1bn dealBenefiting from existing trends that are accelerating through the global health crisis, Cytel is riding the tailwinds of pharma R&D growth and the push to make R&D spend more efficient.